Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Provided By Globe Newswire
Last update: Aug 10, 2022
- Oral fadraciclib demonstrated good tolerability with continuous dosing;
anticipate entering Phase 2 POC stage in 2H 2022 –
13.07
+4.84 (+58.81%)
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/18/2025, 8:00:01 PM)
After market: 5.12 -0.37 (-6.78%)5.4923
+0.18 (+3.43%)
Find more stocks in the Stock Screener
CYCC Latest News and Analysis
